Log in for full access to this activity, if you are registered.

Registration Options

Activity Date: 04/19/2015

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Gender Dysphoria has received increasing attention as a treatable condition as part of the transgender health care equity movement in the United States. According to the Diagnostic and Statistical Manual of Mental Disorders, gender dysphoria is diagnosed when an individual experiences clinically significant discomfort in their assigned gender role and wishes to live in the opposite gender role. The reported prevalence rates are 1 in 11,900 male-to-female (MTF) trans-persons and 1 in 30,400 female-to-male (FTM) trans-persons, although it appears that the rates may be higher in certain populations, such as military veterans. In many cases, patients may elect to undergo a social and physiologic change to their preferred gender. Options for undergoing this change may include exogenous cross-sex hormone administration, electrolysis, psychotherapy, and surgical interventions, all of which involve specialized knowledge by practitioners from a variety of disciplines to include pharmacy. 

In addition to his role as Associate Chairman and Professor of Psychiatry at East Tennessee State University, George Brown, MD, DFAPA is also a Psychosocial Rehabilitation and Recovery Psychiatrist at the Mountain Home VA Medical Center. He recently completed a 2-year term in the Office of Health Equity for Veterans Affairs in Washington D.C. and has served as a coauthor on the Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. He provides national training programs in the use of cross-sex hormones for the VA. In this session, he will address the epidemiology, diagnostics and barriers to care for individuals with gender dysphoria, as well as published standards of care to assist pharmacists in creating pharmacotherapeutic treatment plans for transgender individuals.

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation and the self-assessment questions at the end of the activity. (login first)
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course will be provided at the CPNP 2015 Annual Meeting, April 19-22, 2015. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Learning Objectives

  1. Describe the epidemiology and diagnostic criteria for gender dysphoria.
  2. Evaluate common psychosocial issues and barriers to health care related to gender dysphoria and its relation to healthcare professionals.
  3. Apply the published standards of care, including endocrine practice guidelines, to manage patients with gender dysphoria.
  4. Create a pharmacotherapeutic treatment plan for patients with gender dysphoria, including decisions about preventive care (that specifically address HIV/AIDS, suicide, and violence) and long-term health maintenance.

Continuing Education Credit and Disclosures

Activity Date: 04/19/2015
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-002-L01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-002-L01-P (1.0 contact hours).

Grant Support

This activity is partially supported by an educational grant from Sunovion Pharmaceuticals, Inc.